Open Questions: Cell

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Cell'
open ⚖ 1500
How do tanycytes interact with pathology?
📑 0.50 💥 0.50
open ⚖ 1500
What drives tanycyte senescence?
📑 0.50 💥 0.50
open ⚖ 1500
Can tanycyte function be restored?
📑 0.50 💥 0.50
open ⚖ 1500
How does VTA pathology interact with cortical and limbic Lewy body pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop therapies that selectively protect or restore VTA function?
📑 0.50 💥 0.50
open ⚖ 1500
How does VTA pathology contribute to specific non-motor symptoms?
📑 0.50 💥 0.50
open ⚖ 1500
How does α-synuclein cause granule cell loss?
📑 0.50 💥 0.50
open ⚖ 1500
CRHR1 polymorphisms
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic markers
📑 0.50 💥 0.50
open ⚖ 1500
Can pharmacological approaches enhance AAC function?
📑 0.50 💥 0.50
open ⚖ 1500
What defines selective vulnerability of MS GABAergic neurons?
📑 0.50 💥 0.50
open ⚖ 1500
What are the molecular mechanisms of cuneate plasticity?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise circuit functions of different X94-like subpopulations?
📑 0.50 💥 0.50
open ⚖ 1500
Can ENS biopsy serve as a definitive diagnostic tool?
📑 0.50 💥 0.50
open ⚖ 1500
What is the temporal relationship between cerebellar and cortical pathology?
📑 0.50 💥 0.50
open ⚖ 1500
How does BNST pathology interact with other brain regions in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What is the temporal relationship between BNST dysfunction and cognitive decline?
📑 0.50 💥 0.50
open ⚖ 1500
Does kainate receptor dysfunction precede amyloid pathology in the hippocampus?
📑 0.50 💥 0.50
open ⚖ 1500
Can AIS be protected or regenerated after injury?
📑 0.50 💥 0.50
open ⚖ 1500
Which molecular signatures distinguish NRM subpopulations that bias toward facilitation versus inhibition in chronic disease?
📑 0.50 💥 0.50
open ⚖ 1500
Can early raphe biomarker shifts identify PD subgroups at risk for severe pain and autonomic instability?
📑 0.50 💥 0.50
open ⚖ 1500
Does AD pathology originate in olfactory structures including EpN?
📑 0.50 💥 0.50
open ⚖ 1500
Can early multimodal biomarkers reliably predict CBS underlying pathology before severe disability?
📑 0.50 💥 0.50
open ⚖ 1500
Can NPY/AgRP-targeting therapies improve metabolic outcomes in AD/PD without disrupting normal energy homeostasis?
📑 0.50 💥 0.50
open ⚖ 1500
Does early tau or α-synuclein pathology in the hypothalamus directly dysregulate NPY/AgRP neurons?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relationship between VTA dysfunction and prodromal PD markers?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise molecular mechanisms conferring relative neuroprotection?
📑 0.50 💥 0.50
open ⚖ 1500
What makes granule cells specifically vulnerable in MSA?
📑 0.50 💥 0.50
open ⚖ 1500
How do we balance barrier protection with drug delivery?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal combination of barrier modulators?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop biomarkers predicting barrier breakdown?
📑 0.50 💥 0.50
open ⚖ 1500
How does the BBB change in prodromal disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
Two-photon imaging
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell RNA sequencing
📑 0.50 💥 0.50
open ⚖ 1500
Advanced MRI
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell
📑 0.50 💥 0.50
open ⚖ 1500
Personalized approaches**: How do individual differences in ZI circuit function influence disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
Circuit-specific dysfunction**: How do specific ZI circuits contribute to different symptoms in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic risk factors affect AACs?
📑 0.50 💥 0.50
open ⚖ 1500
How do AACs contribute to hippocampal memory encoding?
📑 0.50 💥 0.50
open ⚖ 1500
Which VGLUT-defined subpopulations are most resilient, and what molecular programs confer that resilience?
📑 0.50 💥 0.50
open ⚖ 1500
When does VGLUT remodeling shift from adaptive plasticity to maladaptive excitotoxic pressure in AD and PD?
📑 0.50 💥 0.50
open ⚖ 1500
Are there cell replacement therapies for TL cell loss?
📑 0.50 💥 0.50
open ⚖ 1500
What pharmacological targets modulate TL cell activity?
📑 0.50 💥 0.50
open ⚖ 1500
Can optogenetic or chemogenetic approaches restore TL function?
📑 0.50 💥 0.50
open ⚖ 1500
What developmental programs specify TL cell fate and connectivity?
📑 0.50 💥 0.50
open ⚖ 1500
How should asymmetric pallidal injury be incorporated into trial stratification frameworks?
📑 0.50 💥 0.50
open ⚖ 1500
Which pallidal microstructural features best track progression in CBD versus PSP-corticobasal phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
Do anti-tau interventions measurably alter pallidal-thalamic circuit metrics before global scales change?
📑 0.50 💥 0.50
open ⚖ 1500
Can pallidal network signatures predict response to targeted rehabilitation or botulinum toxin strategies?
📑 0.50 💥 0.50
open ⚖ 1500
How do environmental factors interact with mutations?
📑 0.50 💥 0.50
open ⚖ 1500
Can sporadic PD involve PINK1 pathway dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specific targeting
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Clinical translation
📑 0.50 💥 0.50
open ⚖ 1500
[Gene therapy](/therapeutics/gene-therapy-neurodegeneration)
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding
📑 0.50 💥 0.50
open ⚖ 1500
Mitochondrial function
📑 0.50 💥 0.50
open ⚖ 1500
Satellite glial cells
📑 0.50 💥 0.50
open ⚖ 1500
Single-Cell Sequencing
📑 0.50 💥 0.50
open ⚖ 1500
Does D2-MSN dysfunction precede motor symptoms in prodromal PD?
📑 0.50 💥 0.50
open ⚖ 1500
Can PDE10A inhibitors provide neuroprotection beyond symptomatic relief?
📑 0.50 💥 0.50
open ⚖ 1500
What makes granule neurons selectively vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
How does cerebellar pathology contribute to cognitive decline?
📑 0.50 💥 0.50
open ⚖ 1500
Can cerebellar function be restored in established disease?
📑 0.50 💥 0.50
open ⚖ 1500
Can BNST-targeted interventions slow disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
GBA gene delivery
📑 0.50 💥 0.50
open ⚖ 1500
Delivery optimization
📑 0.50 💥 0.50
open ⚖ 1500
Engineered GDNF variants
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Optogenetics
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics
📑 0.50 💥 0.50
open ⚖ 1500
Single-Cell Sequencing
📑 0.50 💥 0.50
open ⚖ 1500
Circuit Mapping
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
FKBP5 genotyping
📑 0.50 💥 0.50
open ⚖ 1500
CRH neuron-specific delivery
📑 0.50 💥 0.50
open ⚖ 1500
Allopregnanolone modulation
📑 0.50 💥 0.50
open ⚖ 1500
Vagus nerve stimulation
📑 0.50 💥 0.50
open ⚖ 1500
Oxytocin augmentation
📑 0.50 💥 0.50
open ⚖ 1500
Subtype-specific signaling
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Application to [tauopathies](/mechanisms/tauopathies) and [synucleinopathies](/mechanisms/synucleinopathies)
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
CoA pathway modulators
📑 0.50 💥 0.50
open ⚖ 1500
Iron metabolism
📑 0.50 💥 0.50
open ⚖ 1500
Clinical trials
📑 0.50 💥 0.50
open ⚖ 1500
Early detection
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic Understanding
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development
📑 0.50 💥 0.50
open ⚖ 1500
Genetic profiling
📑 0.50 💥 0.50
open ⚖ 1500
Phenotyping
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker panels
📑 0.50 💥 0.50
open ⚖ 1500
Immune modulation
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic therapy
📑 0.50 💥 0.50
open ⚖ 1500
iPSC-Derived Schwann Cells
📑 0.50 💥 0.50
open ⚖ 1500
Bioengineered Nerve Grafts
📑 0.50 💥 0.50
open ⚖ 1500
3D Bioprinting
📑 0.50 💥 0.50
open ⚖ 1500
Spatial Transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Organoid Systems
📑 0.50 💥 0.50
open ⚖ 1500
PINK1 structure determination
📑 0.50 💥 0.50
open ⚖ 1500
Activation mechanisms
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Can tau PET staging be used prospectively to predict clinical progression?
📑 0.50 💥 0.50
open ⚖ 1500
What role does prion-like tau propagation along anatomical circuits play versus cell-autonomous vulnerability?
📑 0.50 💥 0.50
open ⚖ 1500
How do MS GABAergic neurons interact with other neurodegenerative processes?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop targeted neuroprotective strategies?
📑 0.50 💥 0.50
open ⚖ 1500
How exactly does the cuneate contribute to tactile perception?
📑 0.50 💥 0.50
open ⚖ 1500
Can we enhance cuneate function in aging and disease?
📑 0.50 💥 0.50
open ⚖ 1500
How does cuneate processing differ across species?
📑 0.50 💥 0.50
open ⚖ 1500
Understanding Selective Vulnerability**: Why are certain neuronal populations vulnerable?
📑 0.50 💥 0.50
open ⚖ 1500
Human Melanotroph Biology**: What is the functional significance of the vestigial human intermediate lobe?
📑 0.50 💥 0.50
open ⚖ 1500
Aging**: How does the melanocortin system change with age?
📑 0.50 💥 0.50
open ⚖ 1500
Sex Differences**: Why do males and females differ in melanocortin function?
📑 0.50 💥 0.50
open ⚖ 1500
How does RMTg activity differ in neurodegenerative diseases?
📑 0.50 💥 0.50
open ⚖ 1500
Circadian Regulation**: How does the circadian clock interact with melanotroph function?
📑 0.50 💥 0.50
open ⚖ 1500
Can RMTg modulation improve symptoms in PD or AD?
📑 0.50 💥 0.50
open ⚖ 1500
What is the exact role of RMTg in non-motor symptoms?
📑 0.50 💥 0.50
open ⚖ 1500
Circuit specificity**: Which specific SuM outputs are most critical for memory?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type therapy**: Can targeted SuM cell populations be therapeutically enhanced?
📑 0.50 💥 0.50
open ⚖ 1500
Tau propagation timing**: When does tau first spread to SuM in AD progression?
📑 0.50 💥 0.50
open ⚖ 1500
SuM in PD**: How early does SuM dysfunction occur in PD, and can it serve as a biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Can NBM volumetry serve as a staging biomarker to guide cholinesterase inhibitor treatment timing?
📑 0.50 💥 0.50
open ⚖ 1500
Do PSP and AD produce qualitatively different patterns of BFCN degeneration (subcortical vs cortical cholinergic loss)?
📑 0.50 💥 0.50
open ⚖ 1500
Can targeted neurotrophic delivery prevent the cholinergic component of cognitive decline in PSP?
📑 0.50 💥 0.50
open ⚖ 1500
Can selective nNOS modulation provide neuroprotection without disrupting beneficial NO signaling?
📑 0.50 💥 0.50
open ⚖ 1500
What role does BFCN degeneration play in the behavioral and psychiatric symptoms of tauopathies?
📑 0.50 💥 0.50
open ⚖ 1500
Does S-nitrosylation of specific proteins (parkin, Drp1, GAPDH) drive neurodegeneration, or is it a compensatory response?
📑 0.50 💥 0.50
open ⚖ 1500
Can iNOS inhibitors be developed that cross the blood-brain barrier and selectively reduce pathological NO without affecting endothelial eNOS?
📑 0.50 💥 0.50
open ⚖ 1500
What is the temporal relationship between microglial iNOS induction and dopaminergic neuron loss in PD progression?
📑 0.50 💥 0.50
open ⚖ 1500
How do X94-like cells contribute to specific cognitive functions?
📑 0.50 💥 0.50
open ⚖ 1500
What developmental programs specify X94-like cell fate?
📑 0.50 💥 0.50
open ⚖ 1500
Can X94-like cell function be therapeutically modulated?
📑 0.50 💥 0.50
open ⚖ 1500
What are the best biomarkers for assessing X94-like cell health?
📑 0.50 💥 0.50
open ⚖ 1500
Why do different tau strains show different cell type preferences?
📑 0.50 💥 0.50
open ⚖ 1500
Can genetic or chemogenetic manipulation improve function in disease states?
📑 0.50 💥 0.50
open ⚖ 1500
Can glial pathology occur independently of neuronal pathology?
📑 0.50 💥 0.50
open ⚖ 1500
What pharmacological targets can modulate X94-like cell activity?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the pattern of regional spread?
📑 0.50 💥 0.50
open ⚖ 1500
Can stem cell-derived X94-like cells be used for cell replacement therapy?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop therapies that protect vulnerable cell types?
📑 0.50 💥 0.50
open ⚖ 1500
Can A2A antagonists be combined with D2 agonists for synergistic motor benefit in PD?
📑 0.50 💥 0.50
open ⚖ 1500
What triggers initial alpha-synuclein aggregation in the ENS?
📑 0.50 💥 0.50
open ⚖ 1500
How does the gut microbiome influence alpha-synuclein pathology?
📑 0.50 💥 0.50
open ⚖ 1500
What is the natural history of ENS pathology in at-risk individuals?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal targeting strategy for RGS9 to prevent dyskinesia without impairing therapeutic efficacy?
📑 0.50 💥 0.50
open ⚖ 1500
How do CTIP2 neurons interact with emerging therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Why are CTIP2+ MSNs preferentially vulnerable in HD?
📑 0.50 💥 0.50
open ⚖ 1500
Can we enhance CTIP2 neuroprotection?
📑 0.50 💥 0.50
open ⚖ 1500
What is the role of CTIP2 in AD progression?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic risk factors (APOE, LRRK2, etc.) influence BNST vulnerability?
📑 0.50 💥 0.50
open ⚖ 1500
Can selective GluK1 antagonists provide neuroprotection in AD without disrupting baseline cognition?
📑 0.50 💥 0.50
open ⚖ 1500
Can TARP-auxiliary subunit targeting enable hippocampus-selective kainate modulation for memory enhancement?
📑 0.50 💥 0.50
open ⚖ 1500
What is the role of presynaptic kainate autoreceptors in regulating glutamate release across different disease states?
📑 0.50 💥 0.50
open ⚖ 1500
Can longitudinal VGLUT-focused biomarkers predict symptom domain transitions (for example, cognitive to motor prominence)?
📑 0.50 💥 0.50
open ⚖ 1500
How is AIS length determined during development?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise circuit functions of different AAC populations?
📑 0.50 💥 0.50
open ⚖ 1500
What triggers AIS remodeling in disease?
📑 0.50 💥 0.50
open ⚖ 1500
Subpopulation diversity**: What distinct functional classes of GABAergic TMN neurons exist?
📑 0.50 💥 0.50
open ⚖ 1500
Co-transmission dynamics**: How is the ratio of GABA to histamine regulated?
📑 0.50 💥 0.50
open ⚖ 1500
What are the best biomarkers for assessing AAC health?
📑 0.50 💥 0.50
open ⚖ 1500
Disease-specific vulnerabilities**: What makes GABAergic TMN neurons selectively vulnerable in different neurodegenerative diseases?
📑 0.50 💥 0.50
open ⚖ 1500
How do VA subpopulations differentially contribute to motor vs. cognitive function?
📑 0.50 💥 0.50
open ⚖ 1500
What developmental programs specify AAC fate and connectivity?
📑 0.50 💥 0.50
open ⚖ 1500
What is the extent of TIDA degeneration in PD?
📑 0.50 💥 0.50
open ⚖ 1500
What are the molecular mechanisms of VA vulnerability in different diseases?
📑 0.50 💥 0.50
open ⚖ 1500
How does TIDA dysfunction contribute to non-motor symptoms?
📑 0.50 💥 0.50
open ⚖ 1500
Can VA be more precisely targeted for therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Can prolactin be used as a biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
What are the best therapeutic approaches?
📑 0.50 💥 0.50
open ⚖ 1500
Are there cell replacement therapies for AAC loss?
📑 0.50 💥 0.50
open ⚖ 1500
What are the best approaches for targeting AACs therapeutically?
📑 0.50 💥 0.50
open ⚖ 1500
Early detection**: Can AIS dysfunction serve as a biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Can CA1 subfield volumetry on 7T MRI serve as a primary endpoint for tau-targeting clinical trials?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding**: What are the precise molecular steps of AIS disruption?
📑 0.50 💥 0.50
open ⚖ 1500
Does PART represent a preclinical form of AD or a distinct tauopathy with different underlying mechanisms?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can AIS be protected or restored?
📑 0.50 💥 0.50
open ⚖ 1500
What determines whether tau pathology remains confined to CA1 (PART) or spreads to neocortex (AD)?
📑 0.50 💥 0.50
open ⚖ 1500
Can the differential vulnerability of CA1 versus CA2/CA3 be exploited therapeutically to identify neuroprotective molecules?
📑 0.50 💥 0.50
open ⚖ 1500
What triggers HPA dysregulation in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Can early intervention prevent cognitive decline?
📑 0.50 💥 0.50
open ⚖ 1500
How does AD-related brainstem serotonergic pathology interact with tau network spread and sleep-dependent clearance mechanisms?
📑 0.50 💥 0.50
open ⚖ 1500
How do different cell types respond to glucocorticoids?
📑 0.50 💥 0.50
open ⚖ 1500
What multimodal intervention best restores descending inhibitory reserve in neurodegenerative patients?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal cortisol level for brain health?
📑 0.50 💥 0.50
open ⚖ 1500
Why does the adiponectin paradox occur in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the direction of adiponectin effects (protective vs. harmful)?
📑 0.50 💥 0.50
open ⚖ 1500
Selective vulnerability**: Why is ParGi targeted in α-synucleinopathies?
📑 0.50 💥 0.50
open ⚖ 1500
How can therapeutic targeting be optimized?
📑 0.50 💥 0.50
open ⚖ 1500
Network dysfunction**: How does ParGi impairment affect cortical activity?
📑 0.50 💥 0.50
open ⚖ 1500
What are the optimal biomarkers for adiponectin-related interventions?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development**: Can ParGi imaging predict autonomic dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can ParGi be directly modulated?
📑 0.50 💥 0.50
open ⚖ 1500
Which neurodegenerative phenotypes show earliest decline in functional VGAT loading rather than interneuron number?
📑 0.50 💥 0.50
open ⚖ 1500
Can we target tanycytes therapeutically?
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Cell through bridging wiki connections. See all cross-field connections →

Cross-pollination from Institutions 513 bridges →
Cross-pollination from Genes 1,626 bridges →
Cross-pollination from Experiments 44 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map